🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  2. GENTAMICIN , CEFAZOLIN , VANCOMYCIN , TEDIZOLID , PRISTINAMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM , CEFOTAXIME, CEFTAROLINE FOSAMIL , AMOXICILLIN , OFLOXACIN , CLINDAMYCIN , TIGECYCLINE , LINEZOLID , AMIKACIN , LYMECYCLINE , CEFTRIAXONE , TEICOPLANIN , DOXYCYCLINE , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , Xydalba 500 mg powder for concentrate for solution for infusion, LEVOFLOXACIN , DELAFLOXACIN , CIPROFLOXACIN , CLOXACILLIN , OXACILLIN , DAPTOMYCIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , RIFAMP

    Pari Pharma GmbH

    Catheter related bloodstream infections due to Staphylococcus aureus

    phase 3 small molecule active

    1 trial

  3. GENTAMICINE PANPHARMA 80 mg, solution injectable, Gentamicin Placebo, Metronidazole Biogaran 500 mg Placebo, Natriumchlorid-Lösung 0,9 % Deltamedica, Injektionslösung, METRONIDAZOLE BIOGARAN 500 mg, comprimé pelliculé

    Pari Pharma GmbH

    Acute mesenteric ischemia

    phase 3 small molecule active

    1 trial

  4. GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  5. GLASSIA

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 3 mab completed

    1 trial

  6. GLASSIA

    Takeda

    Graft Versus Host Disease

    phase 3 mab terminated

    1 trial

  7. GLPG CAR T-cell therapy

    Lakefront Biotherapeutics NV

    Hematological Malignancies

    phase 3 gene therapy active

    1 trial

  8. GLPG1690

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule terminated

    2 trials

  9. GLUCOPHAGE 500 mg tabletki powlekane, Placebo

    Bial Portela & Companhia S.A.

    papillary thyroid carcinoma

    phase 3 small molecule active

    1 trial

  10. GLUCOTHERA PLUS

    Lacuna Pharma Pty Ltd

    End-stage Kidney Disease

    phase 3 small molecule active

    1 trial

  11. GSK 2132231A

    GlaxoSmithKline

    Melanoma

    phase 3 small molecule terminated

    1 trial

  12. GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  13. GSK1605786A

    GlaxoSmithKline

    Crohn's Disease

    phase 3 small molecule terminated

    2 trials

  14. GSK2118436

    GlaxoSmithKline

    Cancer

    phase 3 small molecule completed

    1 trial

  15. GSK2585823(CLDM 1%-BPO 3% gel)

    GlaxoSmithKline

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  16. GSK3196165 (Otilimab)

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 3 mab completed

    1 trial

  17. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  18. GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  19. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Pain

    phase 3 small molecule completed

    3 trials

  20. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    4 trials

  21. GW406381

    GlaxoSmithKline

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  22. GW685698/GW642444

    GlaxoSmithKline

    Asthma

    phase 3 small molecule completed

    1 trial

  23. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Seizures Associated With EMAS

    phase 3 small molecule terminated

    1 trial

  24. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Infantile Spasms

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources